Table 3.
Total and Ovarian Cancer–Specific Mortality Associated With Chemotherapy Dose Reduction
| Overall Ovarian Cancer Mortality | Ovarian Cancer–Specific Mortality | |||||||
|---|---|---|---|---|---|---|---|---|
| Dose Reduction | No. | Events | Median Survival, mo |
HR (95% CI)a |
P Valuec | Events | HR (95% CI)a |
P Value |
| Paclitaxel RDI, % | ||||||||
| Dichotomized variable | ||||||||
| ≥85 | 584 | 227 | 44 | 1 [Reference] | .02 | 195 | 1 [Reference] | .007 |
| <85 | 222 | 107 | 39b | 1.35 (1.05–1.73) | 96 | 1.44 (1.11–1.88) | ||
| Four-level variable | ||||||||
| >100 | 141 | 52 | 41 | 0.95 (0.68–1.32) | .005 | 41 | 0.82 (0.57–1.17) | .003 |
| 100–85 | 443 | 175 | 47 | 1 [Reference] | 154 | 1 [Reference] | ||
| <85–70 | 163 | 74 | 43 | 1.21 (0.90–1.62) | 69 | 1.32 (0.98–1.78) | ||
| <70 | 59 | 33 | 28b | 1.78 (1.18–2.69) | 27 | 1.62 (1.03–2.56) | ||
| Carboplatin RDI, % | ||||||||
| Dichotomized variable | ||||||||
| ≥85 | 339 | 135 | 47 | 1 [Reference] | .05 | 114 | 1 [Reference] | .03 |
| <85 | 467 | 199 | 40 | 1.28 (1.00–1.64) | 177 | 1.35 (1.03–1.76) | ||
| Four-level variable | ||||||||
| >100 | 89 | 41 | 54 | 1.05 (0.71–1.56) | .29 | 34 | 0.98 (0.64–1.51) | .17 |
| 100–85 | 250 | 94 | 46 | 1 [Reference] | 80 | 1 [Reference] | ||
| <85–70 | 262 | 116 | 40 | 1.38 (1.03–1.85) | 103 | 1.42 (1.04–1.94) | ||
| <70 | 205 | 83 | 41 | 1.16 (0.82–1.64) | 74 | 1.19 (0.82–1.73) | ||
| Average RDI, % | ||||||||
| Dichotomized variable | ||||||||
| ≥85 | 465 | 177 | 46 | 1 [Reference] | .04 | 151 | 1 [Reference] | .02 |
| <85 | 341 | 157 | 39b | 1.29 (1.01–1.64) | 140 | 1.36 (1.05–1.77) | ||
| Four-level variable | ||||||||
| >100 | 79 | 35 | 54 | 0.84 (0.57–1.25) | .006 | 29 | 0.78 (0.51–1.20) | .003 |
| 100–85 | 386 | 142 | 44 | 1 [Reference] | 122 | 1 [Reference] | ||
| <85–70 | 253 | 113 | 42 | 1.16 (0.88–1.52) | 101 | 1.21 (0.90–1.62) | ||
| <70 | 88 | 44 | 28b | 1.62 (1.10–2.37) | 39 | 1.69 (1.12–2.55) | ||
Abbreviations: HR, hazard ratio; RDI, relative dose intensity.
Adjusted for age at diagnosis, race, body mass index at diagnosis, stage, grade, histologic type, toxic effects during chemotherapy, granulocyte colony-stimulating factor use, diabetes mellitus, hypertension, cardiovascular disease, renal disease, and cancer antigen 125 levels after treatment.
P value <.05 (log-rank test).
For each agent's RDI and average RDI, P value for dichotomized variables corresponds to type 3 P value. For the 4-level variables, P value for trend is presented. Type 3 P value tests are an overall test of whether there are significance differences in mortality across levels of exposure. P for trend tests whether there is a significant dose-response relationship.